187 related articles for article (PubMed ID: 32632815)
1. Nuclear PDCD4 Expression Defines a Subset of Luminal B-Like Breast Cancers with Good Prognosis.
Madera S; Chervo MF; Chiauzzi VA; Pereyra MG; Venturutti L; Izzo F; Roldán Deamicis A; Guzman P; Dupont A; Roa JC; Cenciarini ME; Barchuk S; Figurelli S; Lopez Della Vecchia D; Levit C; Lebersztein G; Anfuso F; Castiglioni T; Cortese E; Ares S; Deza EG; Gercovich FG; Proietti CJ; Schillaci R; Cordo Russo RI; Elizalde PV
Horm Cancer; 2020 Oct; 11(5-6):218-239. PubMed ID: 32632815
[TBL] [Abstract][Full Text] [Related]
2. Impact of age, intrinsic subtype and local treatment on long-term local-regional recurrence and breast cancer mortality among low-risk breast cancer patients.
Laurberg T; Alsner J; Tramm T; Jensen V; Lyngholm CD; Christiansen PM; Overgaard J
Acta Oncol; 2017 Jan; 56(1):59-67. PubMed ID: 27846764
[TBL] [Abstract][Full Text] [Related]
3. Intrinsic subtypes from the PAM50 gene expression assay in a population-based breast cancer survivor cohort: prognostication of short- and long-term outcomes.
Caan BJ; Sweeney C; Habel LA; Kwan ML; Kroenke CH; Weltzien EK; Quesenberry CP; Castillo A; Factor RE; Kushi LH; Bernard PS
Cancer Epidemiol Biomarkers Prev; 2014 May; 23(5):725-34. PubMed ID: 24521998
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of intrinsic subtypes in hormone-receptor-positive metastatic breast cancer: systematic review and meta-analysis.
Schettini F; Martínez-Sáez O; Falato C; De Santo I; Conte B; Garcia-Fructuoso I; Gomez-Bravo R; Seguí E; Chic N; Brasó-Maristany F; Paré L; Vidal M; Adamo B; Muñoz M; Pascual T; Ciruelos E; Perou CM; Carey LA; Prat A
ESMO Open; 2023 Jun; 8(3):101214. PubMed ID: 37075698
[TBL] [Abstract][Full Text] [Related]
5. Down-regulation of programmed cell death 4 (PDCD4) is associated with aromatase inhibitor resistance and a poor prognosis in estrogen receptor-positive breast cancer.
Chen Z; Yuan YC; Wang Y; Liu Z; Chan HJ; Chen S
Breast Cancer Res Treat; 2015 Jul; 152(1):29-39. PubMed ID: 26026468
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Value of the Progesterone Receptor by Subtype in Patients with Estrogen Receptor-Positive, HER-2 Negative Breast Cancer.
Van Asten K; Slembrouck L; Olbrecht S; Jongen L; Brouckaert O; Wildiers H; Floris G; Van Limbergen E; Weltens C; Smeets A; Paridaens R; Giobbie-Hurder A; Regan MM; Viale G; Thürlimann B; Vergote I; Christodoulou E; Van Calster B; Neven P
Oncologist; 2019 Feb; 24(2):165-171. PubMed ID: 30171067
[TBL] [Abstract][Full Text] [Related]
7. Quantification of intrinsic subtype ambiguity in Luminal A breast cancer and its relationship to clinical outcomes.
Kumar N; Zhao D; Bhaumik D; Sethi A; Gann PH
BMC Cancer; 2019 Mar; 19(1):215. PubMed ID: 30849944
[TBL] [Abstract][Full Text] [Related]
8. Identifying enhancer-driven subtype-specific prognostic markers in breast cancer based on multi-omics data.
Zhao H; Zhang S; Yin X; Zhang C; Wang L; Liu K; Xu H; Liu W; Bo L; Lin S; Feng K; Lin L; Fei M; Ning S; Wang L
Front Immunol; 2022; 13():990143. PubMed ID: 36304471
[TBL] [Abstract][Full Text] [Related]
9. Long-Term Outcomes of Immunohistochemically Defined Subtypes of Breast Cancer Less Than or Equal to 2 cm After Breast-Conserving Surgery.
Pata G; Guaineri A; Bianchi A; Amoroso V; Pasinetti N; Pasini M
J Surg Res; 2019 Apr; 236():288-299. PubMed ID: 30694768
[TBL] [Abstract][Full Text] [Related]
10. Alterations in the expression of PDCD4 in ductal carcinoma of the breast.
Wen YH; Shi X; Chiriboga L; Matsahashi S; Yee H; Afonja O
Oncol Rep; 2007 Dec; 18(6):1387-93. PubMed ID: 17982621
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Significance of Progesterone Receptor Expression in Estrogen-Receptor Positive, HER2-Negative, Node-Negative Invasive Breast Cancer With a Low Ki-67 Labeling Index.
Ono M; Tsuda H; Yoshida M; Shimizu C; Kinoshita T; Tamura K
Clin Breast Cancer; 2017 Feb; 17(1):41-47. PubMed ID: 27477822
[TBL] [Abstract][Full Text] [Related]
12. Frequent Molecular Subtype Switching and Gene Expression Alterations in Lung and Pleural Metastasis From Luminal A-Type Breast Cancer.
Klebe M; Fremd C; Kriegsmann M; Kriegsmann K; Albrecht T; Thewes V; Kirchner M; Charoentong P; Volk N; Haag J; Wirtz R; Oskarsson T; Schulz A; Heil J; Schneeweiss A; Winter H; Sinn P
JCO Precis Oncol; 2020; 4():. PubMed ID: 32923902
[TBL] [Abstract][Full Text] [Related]
13. [Methylation profiles of genes in breast cancer luminal HER2-negative primary tumor during regional lymphnode metastasis].
Krasnyi AM; Kurevlev SV; Sadekova AA; Sefikhanov TG; Kometova VV; Rodionov VV
Biomed Khim; 2021 Jan; 67(1):88-94. PubMed ID: 33645526
[TBL] [Abstract][Full Text] [Related]
14. Quantification of subtype purity in Luminal A breast cancer predicts clinical characteristics and survival.
Kumar N; Gann PH; McGregor SM; Sethi A
Breast Cancer Res Treat; 2023 Jul; 200(2):225-235. PubMed ID: 37209182
[TBL] [Abstract][Full Text] [Related]
15. Molecular classification predicts survival for breast cancer patients in Vietnam: a single institutional retrospective analysis.
Nguyen CV; Nguyen QT; Vu HTN; Pham KH; Phung HT
Int J Clin Exp Pathol; 2021; 14(3):322-337. PubMed ID: 33786149
[TBL] [Abstract][Full Text] [Related]
16. Association of poor prognosis subtypes of breast cancer with estrogen receptor alpha methylation in Iranian women.
Izadi P; Mehrdad N; Foruzandeh F; Reza NM
Asian Pac J Cancer Prev; 2012; 13(8):4113-7. PubMed ID: 23098526
[TBL] [Abstract][Full Text] [Related]
17. Immune Checkpoint Profiles in Luminal B Breast Cancer (Alliance).
Anurag M; Zhu M; Huang C; Vasaikar S; Wang J; Hoog J; Burugu S; Gao D; Suman V; Zhang XH; Zhang B; Nielsen T; Ellis MJ
J Natl Cancer Inst; 2020 Jul; 112(7):737-746. PubMed ID: 31665365
[TBL] [Abstract][Full Text] [Related]
18. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
[TBL] [Abstract][Full Text] [Related]
19. Individual- and neighborhood-level socioeconomic status and risk of aggressive breast cancer subtypes in a pooled cohort of women from Kaiser Permanente Northern California.
Aoki RF; Uong SP; Gomez SL; Alexeeff SE; Caan BJ; Kushi LH; Torres JM; Guan A; Canchola AJ; Morey BN; Lin K; Kroenke CH
Cancer; 2021 Dec; 127(24):4602-4612. PubMed ID: 34415571
[TBL] [Abstract][Full Text] [Related]
20. Basal-like immunophenotype markers and prognosis in early breast cancer.
Cassol L; Silveira Graudenz M; Zelmanowicz A; Cancela A; Werutsky G; Rovere RK; Garicochea B
Tumori; 2010; 96(6):966-70. PubMed ID: 21388060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]